Mr. Timothy Ko reports

ENTHEON ANNOUNCES TERMINATION OF MENTIS AI AGREEMENT

Further to Entheon Biomedical Corp.'s news release dated Jan. 24, 2025, 1000141080 Ontario Ltd. (Mentis AI) has terminated the letter of intent (LOI) dated Jan. 23, 2025, which set out the terms whereby Entheon would acquire all of the issued and outstanding common shares in the capital of Mentis AI.

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.